Pink Sheet reporters and editors discuss the impact of a study showing cardiovascular benefits for the weight loss drug Wegovy (:45), another attempt to restrict mifepristone access (16:15), and a new threat to the US FDA’s hybrid work policy (26:35). More On These Topics From The Pink Sheet Wegovy’s Cardiovascular Benefits May Improve, But Not Transform, Insurance Coverage In Obesity: https://pink.pharmaintelligence.informa.com/PS148672/Wegovys-Cardiovascular-Benefits-May-Improve-But-Not-Transform-Insurance-Coverage-In-Obesity Obesity Advocates Meet With FDA Commissioner, Push On Difference vs. Short-Term Weight-Loss: https://pink.pharmaintelligence.informa.com/PS148673/Obesity-Advocates-Meet-With-FDA-Commissioner-Push-On-Difference-vs-ShortTerm-WeightLoss New Attack Against FDA’s Mifepristone Approval Targets Potential Water Contamination: https://pink.pharmaintelligence.informa.com/PS148671/New-Attack-Against-FDAs-Mifepristone-Approval-Targets-Potential-Water-Contamination Peter Marks’ Fears May Come True: White House Wants More In-Person Work: https://pink.pharmaintelligence.informa.com/PS148674/Peter-Marks-Fears-May-Come-True-White-House-Wants-More-In-Person-Work

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Transcript

Related